Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Veeco Instruments Inc. in its acquisition of Epiluvac AB
Mandate

Vinge advises Veeco Instruments Inc. in its acquisition of Epiluvac AB

February 01, 2023 M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data Intellectual Property Corporate Tax Employment and Benefits

Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.

Epiluvac’s technology platform combined with Veeco’s global go-to-market capabilities is expected to create a significant long-term growth driver for Veeco. Epiluvac is an early-stage revenue company with 11 employees. The purchase price for the transaction, all payable in cash, is $30 million paid at the time of closing with a potential additional $35 million in performance based earn-outs.

Vinge's team consisted of, among others, Jonas Bergström, Carl Sander, Stina Bengtsson and Robin Sultani (M&A), Sofia Bergenstråhle and Arvid Axelryd (IP), Anna Ståhlklo and Jonna Skog (Employment), Victor Ericsson and Emelie Svanberg (Tax), Nicklas Thorgerzon (IT & GDPR) and Jasmina Skandrani (Project Assistant).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025